Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.8059
-0.0584-6.76%
Post-market: 0.8000-0.0059-0.73%16:41 EDT
Volume:149.23K
Turnover:121.34K
Market Cap:2.71M
PE:-0.05
High:0.8469
Open:0.8410
Low:0.7900
Close:0.8643
52wk High:524.00
52wk Low:0.7900
Shares:3.37M
Float Shares:3.37M
Volume Ratio:0.70
T/O Rate:4.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.8013
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.21
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Clearmind Medicine, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
- -
Office Location:
1220 West 6th Avenue,Suite 101,Vancouver,British Columbia,Canada
Zip Code:
V6H 1A5
Fax:
- -
Introduction:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Directors

Name
Position
Amitay Weiss
Chairman of the Board
Oz Adler
Independent Director
Yehonatan Shachar
Independent Director
Asaf Itzhaik
Director
Hila Kiron Revach
Director

Shareholders

Name
Position
Adi Zuloff Shani
Chief Executive Officer
Alan Rootenberg
Chief Financial Officer
Mark Haden
Vice President of Business Development